Doximity

DOCS US Health Care Health Care Technology
S&P 400
$25.58
+3.52%
Delayed · cached 15 min

Fair value analysis

DOCS
Doximity
Health CareHealth Care Technology
$25.58
Close used for this calculation
$24.39Fair value
Financial DNA Score
Profitability · Returns · Balance Sheet · Efficiency · Growth
68/100
Profitability25/25
Returns12/25
Balance Sheet21/25
Efficiency10/25
Growth12/25
Strong
Quality radar
68Prof.25/25Ret.12/25Eff.10/25B.Sht21/25Growth12/25

Consensus fair value

$24.39
Near FV
▼ -4.7% against the close used
Model range $18.44 – $32.39
The lowest and highest of the models that produced a value. This is the spread of the methods, not a price target.

Price target range & 52-week position

Bear$18.44Fair value$24.39Bull$32.39
FairClose
52-week traded range
52W low $18.0152W high $75.12

The 52-week range is measured from the stored price history, not estimated.

Valuation summary

Trading close to the consensus fair value

Doximity closed at $25.58, 4.9% above the consensus fair value of $24.39 drawn from 7 valuation models.

Financial DNA score 68/100 — Strong. P/E of 26.1x against the 20x sector multiple the P/E model uses.

Quantitative summary only — not investment advice.

All valuation models

DCF Valuation
$32.39
+26.6%
Σ[CF×(1+g)^n/(1.10)^n] + TV/(1.10)^10
g=9%, r=10%, tg=3%, n=10yr
P/E Fair Value
$19.60
-23.4%
EPS × 20x (sector P/E)
EPS=0.98, Sector P/E=20x
Peter Lynch (PEG)
$29.40
+14.9%
EPS × Growth% (PEG = 1 is fair)
EPS=0.98, g=30%
EV/EBITDA
$20.63
-19.3%
(EBITDA × 18x − Net Debt) ÷ Shares
EBITDA=229.3M
Book Value (P/B)
$18.44
-27.9%
BVPS × (ROE−g)÷(r−g) [Justified P/B — RIM-based]
BVPS=4.79, ROE=21.4%, g=6%, r=10%
Reverse DCF
$25.58
+0.0%
Solve for g: Price = Σ[EPS×(1+g)^n/(1.10)^n] + TV
Implied: 10.7% | Historical: 40%
Margin of Safety
$19.50
-23.8%
Avg(DCF, Graham, P/E) × 75% (25% safety buffer)
Avg fair value=26, MoS=25%

Computed on September 12, 2026 from the most recent annual report on file and that day's closing price. Where a company has seen its earnings move sharply since its last annual report, this figure will lag the market.

Educational data only. Not a recommendation to buy, sell or hold any security.

Educational data only. Not a recommendation to buy, sell or hold any security.